This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Darden University of Virginia (USA)
-
Lisa Walker in Saudi Arabia
Wicks, Andrew C.; Nolan, JohnCase DARDEN-E-0435-EBusiness Ethics and Corporate Social ResponsibilityLisa Walker, a Wharton MBA graduate, was assigned to work in Saudi Arabia as part of her position at JPMorgan Chase. Walker has some trepidation, given Saudi Arabia’s posture toward women. Initially, things were good and Walker felt respected and welcomedStarting at €8.20
-
Vulcan Clothing Company
Wicks, Andrew C.; Nolan, John; Mead, JennyCase DARDEN-E-0438-EBusiness Ethics and Corporate Social ResponsibilityAs an advertising consultant for a New York-based clothing company, the protagonist in this case wants to respect and reflect religious diversity in both promotion and publicity. An actress wearing a hijab, the head cover many Muslim women wear in public, has been included in the company's upcoming global ad campaign, sparking concerns about how the campaign will be received in France. Taking into account the friction between political secula...Starting at €8.20
-
Artificial Intelligence Caselets
Wicks, Andrew C.; Nolan, John; Korinek, Anton; Mead, Jenny; Gillespie, KevinCase DARDEN-E-0437-EBusiness Ethics and Corporate Social ResponsibilityThis set of caselets gets to the heart of the ethical issues embedded within the implementation of artificial intelligence (AI) and other advanced forms of automation technology in the workplace. Employee surveillance, customer privacy, replacing workers with machines and programs, using new data-mining techniques in the hiring process, and more—the multilayered dilemmas these new opportunities present increasingly require managers' careful consi...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20